<code id='69ADA9D3B9'></code><style id='69ADA9D3B9'></style>
    • <acronym id='69ADA9D3B9'></acronym>
      <center id='69ADA9D3B9'><center id='69ADA9D3B9'><tfoot id='69ADA9D3B9'></tfoot></center><abbr id='69ADA9D3B9'><dir id='69ADA9D3B9'><tfoot id='69ADA9D3B9'></tfoot><noframes id='69ADA9D3B9'>

    • <optgroup id='69ADA9D3B9'><strike id='69ADA9D3B9'><sup id='69ADA9D3B9'></sup></strike><code id='69ADA9D3B9'></code></optgroup>
        1. <b id='69ADA9D3B9'><label id='69ADA9D3B9'><select id='69ADA9D3B9'><dt id='69ADA9D3B9'><span id='69ADA9D3B9'></span></dt></select></label></b><u id='69ADA9D3B9'></u>
          <i id='69ADA9D3B9'><strike id='69ADA9D3B9'><tt id='69ADA9D3B9'><pre id='69ADA9D3B9'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:leisure time    - browse:979
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time